[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Infantil de Mexico Federico Gomez\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651204","phase-1-safety-of-lactobacillus-lb-postbiotic-in-immunocompromised-paediatric-patients-with-diarrhoeal-disease-100651204",false,"NCT07758933","Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease","Prospective Study on the Safety of the Postbiotic Lactobacillus LB (Lactéol®) in Immuocompromised Pediatric Patients With Diarrhoeal Disease Treated at the Federico Gómez Children's Hospital of Mexico.","Inclusion Criteria:\n\n1. Patients under 18 years of age.\n2. Patients under hospital care in Federico Gomez Children's Hospital of Mexico\n3. Patients with diarrhoea (three or more loose or liquid stools in a 24 hour period, Bristol Stool Scale 5, 6 or 7) and either of two conditions:\n\n   1. Immunocompromised patients with diarrhoeal disease within the first 72 hours of initiation\n   2. Immunocompromised patients with chronic diarrhoea (≥15 days of diarrhoea onset,\n4. Patients whose parents or guardians give consent to participate and patients who assent to participate (when applicable)\n\nExclusion Criteria:\n\n1. Non-viable oral or enteral administration of Lactobacillus LB postbiotic (Lactéol®).\n2. Bacteriemia or sepsis.\n3. Haemodynamic instability.\n4. Severe neurological disturbances.\n5. Clinical signs of severe dehydration (prolonged capillary refill time, positive skin fold test, abnormal respiratory pattern, or absence of tears).\n6. Known intolerance or allergy to intervention components (lactose, fructose, sucrose, silicic acid, banana artificial flavour, orange artificial flavour,).\n7. Any exclusion criteria as per investigator assessment.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This prospective, interventional, single-center, open-label, phase 1 clinical trial to assess the safety of the Postbiotic Lactobacillus LB in immunocompromised paediatric patients with diarrhoeal disease will be performed at Federico Gomez Children's Hospital of México. Patients will be screened by investigators from hospitalized patients. For eligible children, parents will be invited to participate in the study and provide written consent, in patients of age 8 years and older, informed assent will also be required. Once enrolled, patients' demographic and stratification information will be obtained from the clinical record when applicable, if not, it will be directly collected by the investigator. Patients who have immunocompromise, as per investigator assessment, irrespective of the cause, will receive Lactobacillus LB (Lactéol®) sachets twice daily for 14 days for patients with acute diarrhoeal disease (\\\u003C72 hours of onset) and for 28 days for patients with chronic diarrhoea (≥15 days). Patients will continue follow-up while receiving treatment in hospital, whereas patients who are discharged during the treatment period will continue follow-up via phone calls once weekly and a final evaluation of outcome variables in outpatient clinic at the end of the intervention. Data regarding adverse events, as well as the stop of diarrhoea (\\\u003C3 bowel movements in 24 hours or return to habitual bowel movement frequency) and improvement in stool consistency (at least one point decrease in Bristol Stool Scale) will be collected in every evaluation. Afterwards, the presence or absence of adverse events will be established with a binomial test. As efficacy evaluation is not the main objective of the study, efficacy will be assessed as exploratory variables as presence or absence of efficacy endpoints with the binomial test. If feasible, results may be stratified according to nutritional status, time of onset of diarrhoea, and treatment compliance.",[27],"Diarrhea",[29,30],"Diarrhoeal disease","immunocompromised","NOT_YET_RECRUITING","2026-08-06",{"date":34,"type":35},"2026-08-11","ACTUAL",{"date":37,"type":20},"2026-07-13",{"date":39,"type":20},"2026-12-15",{"name":41,"class":42},"Hospital Infantil de Mexico Federico Gomez","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":17,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":43},"100504731","phase-1-oral-changes-with-caloric-and-no-caloric-sweeteners-100504731","NCT05852145","Oral Changes With Caloric and no Caloric Sweeteners","Effect of the Consumption of Beverages Added With Stevia Rebaudiana on Oral pH and Dental Biofilm in Adolescents","Inclusion Criteria:\n\n* Habitual consumption of soft drinks\n* Decayed, Missing, and Filled Teeth (DMF) index of at least 3 (considering as caries those lesions that are visible without the tooth needing to be dry)\n* Agree to participate in the study and sign informed consent\n* Parents sign informed consent\n* Any nutritional condition\n\nExclusion Criteria:\n\n* Orthodontic treatment\n* Topical application of fluoride during the last 3 months\n* Having a motor disability that interfered with tooth brushing\n* Xerostomia\n* Antibiotic therapy during the study period\n* Periodontal infections",true,"12 Years",{"count":54,"type":20},52,[23,24],"The objective of this clinical trial is to compare the effect that the intake of beverages without sweeteners, added with non-caloric sweeteners (stevioside) and caloric sweeteners (sucrose) on oral pH and dental biofilm microbiome in Mexican adolescents.\n\nParticipants will drink on different occasions a beverage without sweetener, a beverage added with stevioside or a beverage added with sucrose. The researchers will compare the changes that each one causes in salivary pH, dental biofilm pH, dental biofilm bacterial proliferation and dental biofilm microbiome.",[58,59,60],"pH","Microbiome","Dental Plaque",[62,63,58,64,65,66],"artificial sweetener","stevioside","caries","sucrose","dental biofilm","RECRUITING","2025-10-07",{"date":70,"type":35},"2025-10-09",{"date":72,"type":35},"2025-08-01",{"date":74,"type":20},"2026-04",{"name":41,"class":42},""]